<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Transesophageal echocardiography (TEE) is the gold standard in detecting high-risk (ie, aortic <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e>) and potential sources (ie, <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> [<z:mp ids='MP_0004225'>PFO</z:mp>]) of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We sought to evaluate the additional information and therapeutic impact provided by TEE in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients and to characterize patients in whom TEE is indispensable </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We included 503 consecutive patients (mean age 62.2 years) with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Each patient received TEE and the following routine diagnostics: ultrasound of brain supplying arteries, ECG or Holter-ECG, transthoracic echocardiography, and brain imaging (computed tomography or MRI) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> etiology was classified according to the Trial of Org 10172 in <z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0001297'>Stroke</z:hpo> Treatment (TOAST) criteria </plain></SENT>
<SENT sid="5" pm="."><plain>High-risk sources in TEE were: aortic <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> or plaques &gt; or =4 mm, <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in left atrial cavity/left atrial appendage, spontaneous echo contrast, and left atrial flow velocity &lt;30 cm/s </plain></SENT>
<SENT sid="6" pm="."><plain>Potential sources in TEE were <z:mp ids='MP_0004225'>PFO</z:mp>, <z:hpo ids='HP_0011995'>atrial septal aneurysm</z:hpo>, and aortic plaques &lt;4 mm </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: <z:hpo ids='HP_0001297'>Stroke</z:hpo> etiology was determined by routine diagnostics in 276 of 503 patients (54.9%) </plain></SENT>
<SENT sid="8" pm="."><plain>Of the remaining 227 patients (undetermined etiology), 212 (93.4%) were candidates for oral anticoagulation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OA</z:e>) </plain></SENT>
<SENT sid="9" pm="."><plain>TEE revealed a high-risk source, with indication for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OA</z:e> in 17 of them (8.0%) </plain></SENT>
<SENT sid="10" pm="."><plain>A potential source leading to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OA</z:e> was found in an additional 48 patients (22.6%) </plain></SENT>
<SENT sid="11" pm="."><plain>The remaining 147 patients (69.3%) were treated by platelet inhibitors or <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: TEE strongly influenced secondary prevention and led to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OA</z:e> in one third of our patients with <z:hpo ids='HP_0001297'>stroke</z:hpo> of undetermined etiology </plain></SENT>
<SENT sid="13" pm="."><plain>TEE is indispensable in <z:hpo ids='HP_0000001'>all</z:hpo> patients being candidates for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OA</z:e> when routine diagnostics cannot clarify <z:hpo ids='HP_0001297'>stroke</z:hpo> etiology </plain></SENT>
</text></document>